BIOLITE, INC.
πΉπΌTaiwan
- Country
- πΉπΌTaiwan
- Ownership
- Subsidiary, Holding
- Established
- 2009-10-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.bioliteenergy.com
Clinical Trials
7
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:3
Phase 2:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)β’ Click on a phase to view related trials
Phase 2
4 (57.1%)Phase 1
3 (42.9%)PDC-1421 Treatment in Adult Patients With ADHD
Phase 2
Completed
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PlaceboDrug: PDC-1421 Capsule
- First Posted Date
- 2022-01-21
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT05202327
- Locations
- πΊπΈ
University of California, San Francisco, San Francisco, California, United States
π¨π³Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan
π¨π³National Taiwan University Hospital, Taipei, Taiwan
A Phase I/II Study of PDC-1421 for Treating Depression in Cancer Patients
Phase 1
Not yet recruiting
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: PDC-1421 Capsule
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03833206
- Locations
- πΊπΈ
Cedars-Sinai Health System, Los Angeles, California, United States
A Study of BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Phase 2
Not yet recruiting
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- Drug: BLEX 404 Oral Liquid
- First Posted Date
- 2016-10-26
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02944955
Phase I/II, Evaluate the Safety and Efficacy of BLEX 404 With Docetaxel in Patients With Advanced/Metastatic Triple Negative Breast Cancer.
Phase 1
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- Drug: BLEX 404 Oral Liquid
- First Posted Date
- 2016-06-16
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02802423
A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD)
Phase 2
Completed
- Conditions
- Attention-Deficit Hyperactivity Disorder (ADHD)
- Interventions
- Drug: PDC-1421 Capsule
- First Posted Date
- 2016-03-04
- Last Posted Date
- 2021-12-01
- Lead Sponsor
- BioLite, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02699086
- Locations
- πΊπΈ
UCSF Medical Center, San Francisco, California, United States
- Prev
- 1
- 2
- Next
News
No news found